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In this issue of Chemistry & Biology, Winkler and colleagues describe the discovery and preclinical develop-
ment of IPI-145, a new inhibitor of the phosphoinositide 3-kinase (PI3K) isoforms p110d and p110g that have
entered clinical trials.The phosphoinositide 3-kinases (PI3Ks)
are a family of lipid kinases of which there
are eight distinct catalytic subunits ex-
pressed in mammalian cells. Most efforts
to date have been focused on developing
inhibitors against the class I PI3Ks p110a,
p110b, p110g, and/or p110d, which use
PI(4,5)P2 as their preferred substrate to
produce PIP3 at the plasma membrane.
PIP3 serves as a membrane tether for
many proteins, including Akt, and, as
such, connects receptor tyrosine kinases
and G protein coupled receptors to intra-
cellular signaling networks (Okkenhaug,
2013). A number of drugs target all the
class I PI3K isoforms with similar efficacy,
and such compounds are being pro-
gressed through the clinic, primarily to
treat nonhematological malignancies
(Engelman, 2009). Significant progress
has also been made in the design of
inhibitors that discriminate among the
different class I PI3K isoforms. Both
p110g and p110d are expressed at
much higher levels in cells of the immune
system than in other cell types. Therefore,
by targeting one or both of these iso-
forms, one can selectively block PI3K
signaling in leukocytes with minimal
effect on other tissues and organs
(Banham-Hall et al., 2012).
Previously, the p110d-selective inhibi-
tor IC87114 and/or the p110g selective
inhibitor AS605240, often in combination
with PI3K knockout and knockin mice,
have been evaluated in mouse models
of asthma, arthritis, and/or lupus (Ban-
ham-Hall et al., 2012). Broadly speaking,
p110d inhibitors block lymphocyte func-
tion, whereas p110g inhibitors block
innate immune cell migration and func-
tion. This is best demonstrated in
mouse models of asthma, where genetic
or pharmacological inhibition of p110dreduced type 2 T cell responses, whereas
inhibition of p110g prevented eosinophil
recruitment (Nashed et al., 2007; Takeda
et al., 2009). However, dual inhibition of
p110d and p110g was found to be more
effective in an antibody-induced arthritis
model where pathology is thought to
mainly be contributed by innate immune
cells (Randis et al., 2008).
Given the often nonoverlapping func-
tions of p110d and p110g in immune cells,
the rationale for inhibiting both is clear.
Kevan Shokat and colleagues first
described a dual p110d-p110g selective
compound SW14 and found this to be
more potent than a p110d-selective
compound at blocking TNF-a in a cell-
based screen (Williams et al., 2010).
However, dual p110g-p110d inhibition
also presents potential risks, because
p110d and p110g dual-deficient mice
show severe pathology, probably linked
to inappropriate T cell activation, which
is presumed to result from profound
T cell lymphopenia caused by a block
in T cell development (Ji et al., 2007).
A profound depletion of thymocytes was
also observed after administration of
the p110d-p110g dual-specific inhibitor
CAL-130 (Subramaniam et al., 2012).
IPI-145, which was originally developed
by Intellikine as INK-1197, is a p110d-
selective inhibitor that, at higher concen-
tration, is designed to also inhibit p110g.
IPI-145 is remarkably similar in structure
to GS-1101 (now called Idelalisib), which
Gilead acquired from Calistoga Pharma-
ceuticals in 2011. To help distinguish
between the effect of dual inhibition of
p110d and p110g versus inhibition of
p110d alone, another new compound
IPI-3063, which is very potent and selec-
tive for p110d, was used. In this issue of
Chemistry & Biology, Winkler et al. (2013)Chemistry & Biology 20, November 21, 2013 ªcompared the cellular IC50 values of GS-
1101, IPI-145, and IPI-3063 in cell-based
assays, using Akt phosphorylation as a
readout for PI3K activity (summarized
here in Figure 1). These results indicate
that IPI-145 and GS-1101 are about 50-
to 100-fold selective for p110d over
p110g, respectively. However, IPI-145 is
more potent than GS-1101, and p110g
inhibition can be achieved at relatively
low IPI-145 concentrations, which are
readily achievable in vivo. It is also worth
noting that, at higher concentrations,
both IPI-145 andGS-1101 show inhibitory
activity toward p110b. The consequence,
if any, of concomitant p110b inhibition
is not considered further in the current
study, but should not be ignored,
especially as p110b can contribute to
antibody dependent neutrophil activation
(Kulkarni et al., 2011). Because IPI-145 is
more potent against p110d than against
p110g, Winkler et al. (2013) suggest that
they can gradually include p110g inhibi-
tion by increasing the dose of the drug.
In order to demonstrate that IPI-145 can
inhibit a p110g-dependent response
in vivo, a rat air pouch model was used.
In this model, it has previously been
demonstrated that p110g is required for
the recruitment of neutrophils to KC/
GRO—an IL-8 family chemokine. IPI-145
administered at 10 mg/kg, resulting in
plasma levels exceeding 100 nM, pre-
vented neutrophil recruitment. This con-
centration should be sufficient to block
p110g as well as p110d. By contrast,
IPI-3063 administered at 50 mg/kg
showed no inhibition of neutrophil
recruitment, nor did a lower dose of
1 mg/kg of IPI-145. These results confirm
that p110d does not inhibit neutrophil
recruitment and demonstrate that, at
10 mg/kg, IPI-145 effectively inhibits2013 Elsevier Ltd All rights reserved 1309
Figure 1. Chemical Structure and PI3K Isoform Selectivity of GS-1101, IPI-145, and IPI-3063
Structures and cellular IC50 values (nM) against the PI3K p110a, p110b, p110d, and p110g isoforms
are shown as reported by Winkler et al. (2013) in this issue. PI3K activity, as determined by Akt phos-
phorylation, was measured in SCOV cells stimulated with serum (p110a), 786-0 cells stimulated with
serum (p110b), RAJI cells stimulated with anti-IgM (p110d), or RAW264.7 cells stimulated with C5a
(p110g). Enzymatic IC50 values (nM) measured in presence of 3 mM ATP are shown in brackets for
GS-1101 and IPI-145.
Chemistry & Biology
Previewsp110g as well as p110d. Armed with this
insight, Winkler et al. (2013) tested the
effectiveness of IPI-145 in rat models of
arthritis and asthma and a mouse model
of lupus. In the arthritis model, therapeutic
administration of IPI-145 caused a dose-
dependent reduction of ankle swelling.
The maximal response was observed
with administration of 10 mg/kg of com-
pound, but doses as low as 0.5 mg/kg
also gave significant results. However,
only the 10 mg/kg dose blocked cellular
influx into the joints and eliminated
ankle swelling completely, suggesting
that p110g inhibition was required to
completely reverse ankle swelling. IPI-
145 also effectively blocked eosinophil
recruitment and cytokine production in
the asthma model and reduced auto-
antibody production, proteinuria, and
histopathology in the lupus model. In
each case, maximal effect was achieved
with 10 mg/kg doses, whereas partial
responses were observed with 1 mg/kg
doses predicted to only inhibit p110d.1310 Chemistry & Biology 20, November 21,The authors do not report whether they
observed pathologies associated with
dual p110g-p110d inhibition, but this
could be a caveat, at least for long term
administration of high doses of IPI-145.
Both IPI-145 and GS-1101 are showing
promise as anti-leukemic agents and are
moving rapidly through phase II/III clinical
trials. In addition, IPI-145 is being evalu-
ated for the treatment of allergic asthma
and severe rheumatoid arthritis in phase
II trials. The preclinical data presented
here provide an important rationale for
progressing IPI-145 through these trials,
the results from which are keenly antici-
pated. In addition, IPI-145 may show a
benefit in T cell acute lymphoblastic
leukemia, where both p110d and p110g
contribute to cell survival proliferation
(Subramaniam et al., 2012). Finally, the
recent discovery of primary immune
deficient patients with activating muta-
tions in the PIK3CD gene, which encodes
p110d, suggest that inhibitors such as
IPI-3063, or indeed low doses of IPI-145,2013 ª2013 Elsevier Ltd All rights reservedmay help restore normal immune function
in some patients (Angulo et al., 2013;
Lucas et al., 2013).REFERENCES
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